Why the study?
Do bDMARDs/tsDMARDs increase the risk of hospitalisation or death related to seasonal influenza in patients with inflammatory joint diseases?
Do bDMARDs/tsDMARDs increase the risk of hospitalisation or death related to seasonal influenza in patients with inflammatory joint diseases?
Answers are grounded in this paper and cite their sources.
Patients with inflammatory joint diseases face a 50-100% increased risk of hospitalization and death from COVID-19 and influenza, but targeted therapies (bDMARDs/tsDMARDs) do not appear to exacerbate this risk.
In absolute terms, COVID-19 in IJD outnumbers that of average seasonal influenza, but IJD entails a 50%-100% increase in risk for hospitalisation and death for both types of infections, which is largely dependent on associated comorbidities. Overall, bDMARDs/tsDMARDs do not seem to confer additional risk for hospitalisation or death related to seasonal influenza.
No takes yet. Share an insight, caveat, or question.
Bower et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: